1例卡培他滨联合奥沙利铂致非糖尿病患者血糖升高的病例分析  被引量:1

Analysis of a case of capecitabine plus oxaliplatin-induced hyperglycemia in non-diabetic patients

在线阅读下载全文

作  者:董利森 王越[3] 邬旭日 刘俊祥 苏长海[1,2] DONG Lisen;WANG Yue;WU Xuri;LIU Junxiang;SU Changhai(Inner Mongolia Medical University,Hohhot,Inner Mongolia,010050,China;Pharmacy Department,Ordos Central Hos-pital,Ordos,Inner Mongolia,017000,China;Dalat Maternal and Child Health Hospital,Dalat,Inner Mongolia,014300,China;Department of Endocrinology,Ordos Central Hospital,Ordos,Inner Mongolia,017000,China)

机构地区:[1]内蒙古医科大学,内蒙古呼和浩特010050 [2]鄂尔多斯市中心医院药剂科,内蒙古鄂尔多斯017000 [3]达拉特旗妇幼保健院,内蒙古达拉特旗014300 [4]鄂尔多斯市中心医院内分泌科,内蒙古鄂尔多斯017000

出  处:《肿瘤药学》2021年第5期645-650,共6页Anti-Tumor Pharmacy

摘  要:结直肠癌是一种常见的消化道恶性肿瘤。目前,指南推荐结直肠癌术后使用卡培他滨联合奥沙利铂作为辅助化疗方案,化疗过程中常出现手足综合征、恶心、白细胞减少等不良反应,较少引起血糖异常。本文报道1例37岁男性结肠癌患者(既往无糖尿病)术后使用卡培他滨联合奥沙利铂化疗5个周期后,血糖持续升高;化疗第7周期后,停用卡培他滨和奥沙利铂,给予胰岛素及口服降糖药物治疗,患者血糖逐渐好转。停用化疗药物6个月后,患者仅服用二甲双胍即可控制血糖正常。Colorectal cancer is a common gastrointestinal cancer. At present, it is recommended to use capecitabine combined with oxaliplatin as adjuvant chemotherapy after colorectal cancer operation. Adverse reactions, such as hand-foot syndrome, nausea, leukopenia and so on, often occurred in the course of such combined chemotherapy, but it is rare to cause abnormal blood glucose. Here was reported a case of 37 years old male patient with colon cancer(no diabetes in the past), who had his blood glucose level continue to rise after five cycles of chemotherapy with capecitabine and oxaliplatin.After the seventh cycle of chemotherapy, the patient stopped capecitabine and oxaliplatin, and got insulin and oral hypoglycemic drugs, and then had his blood sugar level gradually improved. Six months after stopping chemotherapy drugs, the patient could control his blood sugar normal only by metformin.

关 键 词:奥沙利铂 卡培他滨 血糖升高 药物不良反应 

分 类 号:R735.35[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象